These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 21281870)

  • 1. Effects of omalizumab on changes in pulmonary function induced by controlled cat room challenge.
    Corren J; Wood RA; Patel D; Zhu J; Yegin A; Dhillon G; Fish JE
    J Allergy Clin Immunol; 2011 Feb; 127(2):398-405. PubMed ID: 21281870
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of omalizumab in cat-allergic patients with moderate-to-severe persistent asthma.
    Massanari M; Kianifard F; Zeldin RK; Geba GP
    Allergy Asthma Proc; 2009; 30(5):534-9. PubMed ID: 19467177
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protective effect of montelukast on lower and upper respiratory tract responses to short-term cat allergen exposure.
    Perry TT; Corren J; Philip G; Kim EH; Conover-Walker MK; Malice MP; Massaad R; Dass SB; Reiss TF; Wood RA
    Ann Allergy Asthma Immunol; 2004 Nov; 93(5):431-8. PubMed ID: 15562881
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Omalizumab protects against allergen- induced bronchoconstriction in allergic (immunoglobulin E-mediated) asthma.
    Zielen S; Lieb A; De La Motte S; Wagner F; de Monchy J; Fuhr R; Munzu C; Koehne-Voss S; Rivière GJ; Kaiser G; Erpenbeck VJ
    Int Arch Allergy Immunol; 2013; 160(1):102-10. PubMed ID: 22948442
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of omalizumab on basophil and mast cell responses using an intranasal cat allergen challenge.
    Eckman JA; Sterba PM; Kelly D; Alexander V; Liu MC; Bochner BS; Macglashan DW; Saini SS
    J Allergy Clin Immunol; 2010 Apr; 125(4):889-895.e7. PubMed ID: 19962744
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized, double-blind, placebo-controlled trial of the effect of zafirlukast on upper and lower respiratory responses to cat challenge.
    Phipatanakul W; Eggleston PA; Conover-Walker MK; Kesavanathan J; Sweitzer D; Wood RA
    J Allergy Clin Immunol; 2000 Apr; 105(4):704-10. PubMed ID: 10756219
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-IgE (omalizumab) inhibits late-phase reactions and inflammatory cells after repeat skin allergen challenge.
    Ong YE; Menzies-Gow A; Barkans J; Benyahia F; Ou TT; Ying S; Kay AB
    J Allergy Clin Immunol; 2005 Sep; 116(3):558-64. PubMed ID: 16159624
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of omalizumab, a humanized monoclonal anti-IgE antibody, on nasal reactivity to allergen and local IgE synthesis.
    Corren J; Diaz-Sanchez D; Saxon A; Deniz Y; Reimann J; Sinclair D; Davancaze T; Adelman D
    Ann Allergy Asthma Immunol; 2004 Sep; 93(3):243-8. PubMed ID: 15478383
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Omalizumab in children with inadequately controlled severe allergic (IgE-mediated) asthma.
    Kulus M; Hébert J; Garcia E; Fowler Taylor A; Fernandez Vidaurre C; Blogg M
    Curr Med Res Opin; 2010 Jun; 26(6):1285-93. PubMed ID: 20377320
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma.
    Gevaert P; Calus L; Van Zele T; Blomme K; De Ruyck N; Bauters W; Hellings P; Brusselle G; De Bacquer D; van Cauwenberge P; Bachert C
    J Allergy Clin Immunol; 2013 Jan; 131(1):110-6.e1. PubMed ID: 23021878
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A 26-week, randomized, double-blind, placebo-controlled, multicenter study to evaluate the effect of omalizumab on asthma control in patients with persistent allergic asthma.
    Bardelas J; Figliomeni M; Kianifard F; Meng X
    J Asthma; 2012 Mar; 49(2):144-52. PubMed ID: 22277052
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of omalizumab on adenosine 5'-monophosphate responsiveness in subjects with allergic asthma.
    Prieto L; Gutiérrez V; Colás C; Tabar A; Pérez-Francés C; Bruno L; Uixera S
    Int Arch Allergy Immunol; 2006; 139(2):122-31. PubMed ID: 16374021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of adding omalizumab, an anti-immunoglobulin E antibody, on airway wall thickening in asthma.
    Hoshino M; Ohtawa J
    Respiration; 2012; 83(6):520-8. PubMed ID: 22236804
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma.
    Ayres JG; Higgins B; Chilvers ER; Ayre G; Blogg M; Fox H
    Allergy; 2004 Jul; 59(7):701-8. PubMed ID: 15180756
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunological and clinical changes in allergic asthmatics following treatment with omalizumab.
    Noga O; Hanf G; Kunkel G
    Int Arch Allergy Immunol; 2003 May; 131(1):46-52. PubMed ID: 12759489
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR.
    Vignola AM; Humbert M; Bousquet J; Boulet LP; Hedgecock S; Blogg M; Fox H; Surrey K
    Allergy; 2004 Jul; 59(7):709-17. PubMed ID: 15180757
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of fexofenadine in the prophylactic control of cat allergen-induced allergic rhinitis.
    Berkowitz RB; Braker S; Lutz C; Jones P; Meeves S; Qiu C; Varghese ST; Georges G
    Ann Allergy Asthma Immunol; 2006 Feb; 96(2):327-33. PubMed ID: 16498855
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma.
    Holgate ST; Chuchalin AG; Hébert J; Lötvall J; Persson GB; Chung KF; Bousquet J; Kerstjens HA; Fox H; Thirlwell J; Cioppa GD;
    Clin Exp Allergy; 2004 Apr; 34(4):632-8. PubMed ID: 15080818
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of omalizumab in patients with inadequately controlled severe persistent allergic asthma: an open-label study.
    Niven R; Chung KF; Panahloo Z; Blogg M; Ayre G
    Respir Med; 2008 Oct; 102(10):1371-8. PubMed ID: 18657960
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of long-term safety of the anti-IgE antibody, omalizumab, in children with allergic asthma.
    Berger W; Gupta N; McAlary M; Fowler-Taylor A
    Ann Allergy Asthma Immunol; 2003 Aug; 91(2):182-8. PubMed ID: 12952113
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.